135 7 DELIRIUM | PART THREE 16. Schuurmans MJ, Shortridge-Baggett LM, Duursma SA. The Delirium Observation Screening Scale: a screening instrument for delirium. Res Theory Nurs Pract 2003;17:31-50. 17. Neefjes EC, van der Vorst MJ, Boddaert MS et al. Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer. BMC Cancer 2019;19:160. 18. Trzepacz PT, Mittal D, Torres R, et al. Validation of the Delirium Rating Scalerevised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci 2001;13:229-42. 19. CTCAE version 4.03. Available at https:// evs.nci.nih.gov/ftp1/CTCAE/About.htlm. (22 March 2019, date last accessed). 20. Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002;43:175-82. 21. Fuglsang A. Futility rules in bioequivalence trials with sequential designs. AAPS J 2014;16:79-82. 22. Neefjes EC, van der Vorst MJ, Verdegaal BA et al. Identification of patients with cancer with a high risk to develop delirium. Cancer Med 2017;6:1861-70. 23. Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry 2003;25:345-52. 24. Maclullich AM, Anand A, Davis DH et al. New horizons in the pathogenesis, assessment and management of delirium. Age and Ageing 2013;42:667-74. 25. Maldonado JR. Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry 2018;33:1428-57. 26. Kim SW, Yoo JA, Lee SY et al. Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol 2010;25:298-302. 27. Hui D, Frisbee-Hume S, Wilson A et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA 2017;318:1047-56. 28. Hui D, Dev R, Bruera A. Neuroleptics in the management of delirium in patients with advanced cancer. Curr Opin Support Palliat Care. 2016:316-23. 29. Gill SS, Bronskill SE, Normand SL et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-86. 30. Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41. 31. Maust DT, Kim HM, Seyfried LS et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015;72:438-45. 32. Yoon HJ, Park KM, Choi WJ et al. Efficacy and safety of haloperidol vs. atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry 2013;13:240. 33. Meagher D, Agar MR, Teodorczuk A. Debate article: Antipsychotic medications are clinically useful for the treatment of delirium. Int J Geriatr Psychiatry 2018;33:1420-27. 34. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry 2018;17:341-56.
RkJQdWJsaXNoZXIy MjY0ODMw